PROCEPT BioRobotics Corporation

NasdaqGM PRCT

PROCEPT BioRobotics Corporation Price to Sales Ratio (P/S) on January 14, 2025: 22.20

PROCEPT BioRobotics Corporation Price to Sales Ratio (P/S) is 22.20 on January 14, 2025, a 20.87% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

PROCEPT BioRobotics Corporation 52-week high Price to Sales Ratio (P/S) is 27.32 on December 04, 2024, which is 23.08% above the current Price to Sales Ratio (P/S).
PROCEPT BioRobotics Corporation 52-week low Price to Sales Ratio (P/S) is 15.52 on April 04, 2024, which is -30.08% below the current Price to Sales Ratio (P/S).
PROCEPT BioRobotics Corporation average Price to Sales Ratio (P/S) for the last 52 weeks is 21.07.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGM: PRCT

PROCEPT BioRobotics Corporation

CEO	Dr. Reza Zadno Ph.D.
IPO Date	Sept. 15, 2021
Location	United States
Headquarters	900 Island Drive
Employees	626
Sector	Technology
Industries Robotics Biotechnology

Description

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.

Key trends

Past 5 years